Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32354800    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32354800 :   free
PDF vom PMID32354800  :  Publisher
PDF vom PMID32354800

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Cardiovascular manifestations and treatment considerations in COVID-19 #MMPMID32354800
  • Kang Y; Chen T; Mui D; Ferrari V; Jagasia D; Scherrer-Crosbie M; Chen Y; Han Y
  • Heart 2020[Aug]; 106 (15): 1132-1141 PMID32354800show ga
  • Since its recognition in December 2019, covid-19 has rapidly spread globally causing a pandemic. Pre-existing comorbidities such as hypertension, diabetes, and cardiovascular disease are associated with a greater severity and higher fatality rate of covid-19. Furthermore, COVID-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress-cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest. The cardiovascular interactions of COVID-19 have similarities to that of severe acute respiratory syndrome, Middle East respiratory syndrome and influenza. Specific cardiovascular considerations are also necessary in supportive treatment with anticoagulation, the continued use of renin-angiotensin-aldosterone system inhibitors, arrhythmia monitoring, immunosuppression or modulation, and mechanical circulatory support.
  • |Angiotensin Receptor Antagonists/therapeutic use[MESH]
  • |Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH]
  • |Anticoagulants/therapeutic use[MESH]
  • |Azithromycin/therapeutic use[MESH]
  • |Betacoronavirus[MESH]
  • |Biomarkers/blood[MESH]
  • |Cardiovascular Diseases/*epidemiology/therapy[MESH]
  • |Chloroquine/therapeutic use[MESH]
  • |Comorbidity[MESH]
  • |Coronavirus Infections/*epidemiology/mortality[MESH]
  • |Cytokine Release Syndrome/epidemiology[MESH]
  • |Disseminated Intravascular Coagulation/epidemiology[MESH]
  • |Extracorporeal Membrane Oxygenation[MESH]
  • |Humans[MESH]
  • |Hydroxychloroquine/therapeutic use[MESH]
  • |Immunosuppressive Agents/therapeutic use[MESH]
  • |Influenza, Human/mortality[MESH]
  • |Lung/metabolism/pathology[MESH]
  • |Myocardium/metabolism/pathology[MESH]
  • |Pandemics[MESH]
  • |Peptidyl-Dipeptidase A/metabolism[MESH]
  • |Pneumonia, Viral/*epidemiology[MESH]
  • |Severe Acute Respiratory Syndrome/mortality[MESH]
  • |Troponin/blood[MESH]
  • |Venous Thromboembolism/epidemiology/prevention & control[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1132 15.106 2020